TORS more effective for early stage throat cancers

 Transoral robotic surgery (TORS) is "more effective" for throat cancers diagnosed in early stages, than radiation treatment, a doctor of a leading hospital in Delhi today claimed.
Fortis Memorial Research Institute (FMRI) has piloted a first of its kind study on patients suffering from early stage oropharyngeal carcinoma (cancer of the mouth, neck and throat).
The study was conducted on 57 patients, who have undergone TORS, under the leadership of Dr Surender Dabas, Director, Head, Neck and Thorax Surgical Oncology, FMRI.
"This novel and path-breaking surgical technique is instrumental in healing patients suffering from HPV negative cancers which are caused mostly due to tobacco consumption.
The study that got published in Oral Oncology journal was conducted between March 2013 to October 2015 on these patients suffering from early stage (I & II) oropharyngeal carcinoma who underwent surgery conducted with the assistance of a surgical robot to remove a tumor from the mouth or throat, the FMRI said.
Out of these 57 patients, 48 were men and nine women.
"In comparison to HPV negative cancers HPV positive cancers are more responsive to chemotherapy and radiation treatment. In India majority (nearly 70 per cent) of all oropharyngeal cancers are HPV negative.
"This is the reason that TORS is a viable treatment option of HPV negative cancers. In order to avoid the side effects of undergoing a traditional open surgery, if the cancer has been caught at an early stage, TORS is adopted," Dabas said.
"For early stages, TORS is more effective than radiation treatment as per the study," he said, during a press conference.
"Posing significant benefits to the patients, it prevents functional impairments to speech and swallowing. It is a fast surgery and precise, intricate and intensive in its execution. The amount of blood loss and the recovery time required post the operation is remarkably minimal. As this method can be implemented without prior chemo therapy, it allows the patient to be free of any toxicity associated with the same" he added.
The incidence of oropharyngeal carcinoma is increasing in India. As per estimates, there were estimated 38,691 new cases of oropharyngeal cancers in India in 2012, the FMRI said.
As compared to the developed countries, where the increase in the incidence of oropharyngeal carcinoma is mainly attributed to the epidemic increase in the incidence of HPV infection, the leading cause of oropharyngeal carcinoma in India is exposure to tobacco and alcohol. PTI KND SMJ.

Source:http://indiatoday.intoday.in/story/tors-more-effective-for-early-stage-throat-cancers/1/963275.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more